

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8329)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 17.10 of the GEM Listing Rules and the Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the Shareholders and potential investors that based on the preliminary assessment of Group's unaudited consolidated management accounts, it is expected that the consolidated profit attributable to the equity holders of the Company for the six months ended 30 June 2015 may record a decrease by not more than 50% as compared with that for the corresponding period in 2014.

The information contained in this announcement is only the preliminary assessment made by the Board based on the Group's unaudited consolidated management accounts for the six months ended 30 June 2015, and such information has not been reviewed nor audited by the Company's auditors or the Company's audit committee.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Shenzhen Neptunus Interlong Bio-technique Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 17.10 of The Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the "**GEM Listing Rules**") and the Inside Information Provisions (as defined under the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the "**SFO**").

* For identification purpose only

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the preliminary assessment of Group’s unaudited consolidated management accounts, it is expected that the consolidated profit attributable to the equity holders of the Company for the six months ended 30 June 2015 may record a decrease by not more than 50% as compared with that for the corresponding period in 2014. Such decrease that may be recorded was mainly due to (i) a decrease in revenue of the manufacturing and selling of medicines segment which resulted from a drop in the sales volume of Compound Liquorice Tablets* (複方甘草片); (ii) a slow pace in the drug tender progress for the new product namely Tegafur, Gimeracil and Oteracil Potassium Tablets* (替吉奧片); and (iii) an increase in the Group’s research and development input.

The Company is still in the process of preparing and finalizing the Group’s interim results for the six months ended 30 June 2015. The information contained in this announcement is only a preliminary assessment made by the Board based on the Group’s unaudited consolidated management accounts for the six months ended 30 June 2015, and such information has not been audited nor reviewed by the Company’s auditors or the Company’s audit committee. Shareholders and potential investors are advised to read carefully the Group’s interim results announcement for six months ended 30 June 2015 which is expected to be published in August 2015.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Shenzhen Neptunus Interlong Bio-technique Company Limited*
Zhang Feng
Chairman

Shenzhen, the PRC, 15 July 2015

As at the date of this announcement, the executive Directors are Mr. Zhang Feng, Mr. Chai Xiang Dong and Mr. Xu Yan He; the non-executive Directors are Mr. Liu Zhan Jun, Ms. Yu Lin and Mr. Song Ting Jiu; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Mr. Yu Bo.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from its date of publication and on the Company’s website at www.interlong.com.

* For identification purpose only